Changing the Future of PNH Care Through Global Collaboration – The Max Foundation
The Max Foundation shared a post on LinkedIn:
“For physicians like Dr. Mipsang Lama in Nepal, there was a time when the rare and devastating blood disorder of Paroxysmal Nocturnal Hemoglobinuria (PNH) could be identified but not truly treated.
Care meant repeated transfusions, temporary stabilization, and watching patients live with constant uncertainty.
Then, thanks to our partnership with Novartis Global Health and the International PNH Interest Group, access to treatment and training changed that!
Within weeks, patients began regaining strength. Conversations shifted from survival to possibility.
For Dr. Lama, it was more than a clinical change. It was the ability to finally offer hope alongside care.
He shared, ‘To those working in global health and rare disease access, your work has a deeply human impact. PNH may be rare, but the suffering it causes is real and significant. Today, for the first time, we can say with confidence that ‘it is treatable.’ ”

Stay updated with Hemostasis Today.
-
Jul 10, 2026, 09:57Katherine Rozycki: The Future of Haematology Through Education
-
Jul 10, 2026, 09:42Biljana Andrić: The Best Transfusion Is Often The One That Can Be Avoided
-
Jul 10, 2026, 09:27Farnaz Poorhasan: FFP is More Than Just Frozen Blood Components
-
Jul 10, 2026, 02:32Nina Laue: Looking Forward to Connecting and Collaborating at ISTH 2026
-
Jul 10, 2026, 02:19Anita Singla: Thalassemia Screening in Pregnancy Has a Lifelong Impact
-
Jul 10, 2026, 02:07Ruman Bashir: Immune Thrombocytopenia in Pregnancy
-
Jul 9, 2026, 19:20Bradley Maron: The Beginning of a New Chapter for Circulation
-
Jul 9, 2026, 19:00Wolfgang Miesbach: ISTH 2026 Showcases the Future of Gene Therapy
-
Jul 9, 2026, 18:21Martin Vanden Eede: Can We Safely Reduce Anticoagulation During ECMO?